TMC114/rtv

DRUG2 trials

Sponsors

Tibotec Pharmaceuticals, Ireland

Conditions

HIV InfectionHIV Infections

Phase 2

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

CompletedNCT00071097

Tibotec Pharmaceuticals, IrelandHIV Infections

Start: 2003-10-31End: 2007-11-30Updated: 2016-09-20

Phase 3

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

CompletedNCT00110877

Tibotec Pharmaceuticals, IrelandHIV Infection

Start: 2005-04-30End: 2011-10-31Updated: 2015-07-03

Related Papers

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

2007-07-01229 citations

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

2007-04-01340 citations